Raymond James & Associates Relay Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 66,842 shares of RLAY stock, worth $434,473. This represents 0.0% of its overall portfolio holdings.
Number of Shares
66,842
Previous 36,977
80.77%
Holding current value
$434,473
Previous $241,000
96.27%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding RLAY
# of Institutions
214Shares Held
173MCall Options Held
0Put Options Held
36.1K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$181 Million0.77% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct13.4MShares$87.4 Million0.1% of portfolio
-
Commodore Capital LP New York, NY13.4MShares$86.8 Million4.31% of portfolio
-
Casdin Capital, LLC New York, NY11.4MShares$74.1 Million5.53% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$68.5 Million0.0% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $781M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...